Diclofenac Sodium, 0.1% (Voltaren Ophtha), Versus Sodium Chloride, 5%, in the Treatment of Filamentary Keratitis

Avisar, Rahamim; Robinson, Anat; Appel, Itiel; Yassur, Yuval; Weinberger, Dov

doi:10.1097/00003226-200003000-00005

Cited by 40 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are two randomized trials with topical diclofenac and topical ketorolac that provide evidence of NSAID efficacy [49, 50]. Oral pilocarpine has been demonstrated to increase tear production and flow, thus it improves the symptoms of DES in Sjögren's syndrome patients [51].…”

Section: Treatment Of Dry Eye Syndrome (Des)mentioning

confidence: 99%

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Yavuz

Pehlivan

Ünlü

2012

The Scientific World Journal

View full text Add to dashboard Cite

Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by decreased tear production or increased evaporation. Changes in tear composition also promote inflammation on the ocular surface by various mechanisms. Artificial tear drops, tear retention treatment, stimulation of tear secretion, or anti-inflammatory drugs may be used for dry eye treatment according to the severity of the disease. For untreated patients, the risk of ocular infection increases at considerable level and clinical course of the disease may proceed up to infection, corneal ulcer, and blindness. Artificial tears and/or punctual occlusions are used for tear replacement or preservation. New treatment approaches are designed to modify the underlying disease process. For the treatment of severe dry eye disease, cyclosporin A (CsA), the first one of the new generation immunomodulatory drugs, which has an anti-inflammatory effect, is frequently used. CsA has immunosuppressive effects following systemic application. Following local administration of CsA, it is expected to obtain effective drug concentration at the target area and to avoid the various side effects associated with systemic delivery. Microspheres, implants, and liposomes have been developed for administration of CsA subconjunctivally in order to enhance its efficiency.

show abstract

Section: Treatment Of Dry Eye Syndrome (Des)mentioning

confidence: 99%

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Yavuz

Pehlivan

Ünlü

2012

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…[30][31][32] Inhibition of prostaglandins and the arachidonic acid cascade by topical NSAIDs can relieve ocular hyperalgesia. However, in patients with corneal problems, a common phenomenon in pSS patients, the use of topical NSAIDs is associated with corneal-scleral melts, perforation, and severe keratopathy.…”

Section: Topical Nsaidsmentioning

confidence: 99%

Safety of treatments for primary Sjögren’s syndrome

Nimwegen

Moerman

Smitt

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: Primary Sjögren's syndrome (pSS) is a disabling auto-immune disease, affecting exocrine glands and several organs. Areas covered:In this review we analyze the safety of therapies used in pSS. Symptomatic treatment is widely applied due to the good supportive effect and good safety profile. Systemic stimulation of tears and saliva can be successful in pSS. However, cumbersome adverse events can influence the tolerability of this therapy. Evidence for the effectiveness of synthetic DMARDs therapies in pSS is limited, while there is a risk of adverse events. Several studies on biologic DMARD treatment of pSS patients have shown promising efficacy and safety results. Expert opinion: The safety of symptomatic treatment of pSS is very good. However, systemic therapy is necessary to achieve long-term relieve and prevention of organ-damage. Synthetic DMARDs have not shown much efficacy in earlier studies, and their benefits do not weigh up to the possible harms, while biologic DMARDs show promising results regarding efficacy and cause mostly mild adverse events. Many questions remain unanswered regarding safety of DMARDs in pSS. There is a need for well designed studies, in which safety should be evaluated in a uniform manner to be able to compare the results between studies.ARTICLE HISTORY

show abstract

“…The efficacy of topical antiinflamatories was tested in two randomised controlled trials (RCT), one prospective, open label, using diclofenac 0.1% drops (21) and one controlled, parallel group study, comparing diclofenac 0.1% with indomethacin 0.1 % eye drops (22). Both studies showed improvement of the subjective symptoms in the NSAIDs treatment arms, which was not maintained at day 28 in the first study, and was associated with significant worsening of the corneal staining in the diclofenac group in the second study.…”

Section: Topical Treatmentsmentioning

confidence: 99%